Home › Encyclopedia › LL-37 Peptide: Research Status, Identity, and Clinical Trials
Research / Unapproved

LL-37 Peptide: Research Status, Identity, and Clinical Trials

Molecular formulaC205H340N60O53
Molecular weight4493 g/mol
Registered trials61
PubChem CID16198951

Regulatory status

LL-37 is classified as an unapproved research compound. There is no FDA-approved label, brand name, or approved indication for this peptide.

What LL-37 is

LL-37 is a peptide identified by PubChem CID 16198951, with a molecular formula of C205H340N60O53. No approved drug label exists for this compound, so its mechanism and classification are not formally established for clinical use.

Trial footprint

LL-37 and related research appear across 61 registered trials. Among the sample records, one trial examined intratumoral injections of LL-37 for melanoma and was listed as completed in an early-phase combined study. Other registered trials in the broader dataset involve related research areas, such as a completed study of Lactobacillus reuteri plus vitamin D3 in children with atopic dermatitis and a withdrawn study on vitamin D status in joint replacement patients.

FAQ

Is LL-37 FDA approved?
No. LL-37 has no FDA-approved label, brand name, or approved indication. It is currently classified as an unapproved research compound.
What is LL-37?
LL-37 is a peptide with the molecular formula C205H340N60O53, cataloged under PubChem CID 16198951. Because no approved label exists, its formal mechanism of action and drug classification are not established for clinical use.
How many clinical trials involve LL-37?
There are 61 registered trials associated with LL-37 in the dataset reviewed. These include studies at varying stages and statuses, such as completed and withdrawn trials.
Has LL-37 been studied in cancer research?
Yes. One registered trial examined intratumoral injections of LL-37 for melanoma, combining early-phase study designs, and was listed as completed. This reflects a single research record, not evidence of approved use or efficacy.
Are there known side effects of LL-37?
No FDA Adverse Event Reporting System data was available for LL-37 at the time of this review, so no side effect pattern can be summarized from that source.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-11-07